Capillary blood sampling to evaluate SARS-CoV-2 antibody assays.[COVID-19]
Research type
Research Study
Full title
Capillary blood sampling to evaluate SARS-CoV-2 antibody assays: Capillary Testing for COVID-19 (CTC-19) Study.
IRAS ID
284159
Contact name
Kathleen Gillespie
Contact email
Sponsor organisation
University of Bristol
Duration of Study in the UK
2 years, 0 months, 0 days
Research summary
Since first reported in December 2019, the novel SARS-CoV-2 coronavirus has led to a global pandemic, spreading to over 100 countries. Currently specificity issues with COVID-19 Ab assays have limited their use internationally and essential testing has been delayed. Mass antibody (Ab) testing has been identified as a pillar of the national COVID-19 strategy but, as yet there is no reliable method available to identify those who have been previously infected and have recovered. \n\nThis research open to adults aged 18 and above and will aim to recruit 1,000 participants. The study is sponsored by the University of Bristol. Participants will primarily learn/express interest about this study through social media, and electronic methods but may hear also through face to face contacts.\n \nIn this UK feasibility study, we will use a capillary collection (finger prick) of small volume blood samples to validate a laboratory test (assay) to measure antibodies to SARS-CoV-2 (COVID-19) in the general population. Sample collection kits will be posted to participants who express interest and give informed consent to participate. \n\n\n
REC name
North West - Greater Manchester South Research Ethics Committee
REC reference
20/NW/0261
Date of REC Opinion
21 May 2020
REC opinion
Further Information Favourable Opinion